Hongtao B. Liu

Hongtao B. Liu

Hematology

600 Highland Ave
Madison, WI 53792

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 211 publications

Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.

Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.

Journal: Leukemia & lymphoma

Published: August 17, 2026

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Journal: Transplantation and cellular therapy

Published: April 03, 2026

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Journal: Transplantation and cellular therapy

Published: February 12, 2026

Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.

Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.

Journal: Blood advances

Published: May 19, 2025

Editorial Expression of Concern: Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.

Editorial Expression of Concern: Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.

Journal: Oncogene

Published: May 09, 2025

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.

Journal: Blood neoplasia

Published: March 25, 2025

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Journal: Blood advances

Published: February 11, 2025

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 09, 2025

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.

Journal: Blood advances

Published: October 28, 2024

A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers.

A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers.

Journal: Journal of psychopharmacology (Oxford, England)

Published: September 20, 2024

EMC Effect of Tritium and Helium-3 from the JLab MARATHON Experiment.

EMC Effect of Tritium and Helium-3 from the JLab MARATHON Experiment.

Journal: Physical review letters

Published: September 19, 2024

Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.

Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.

Journal: Science translational medicine

Published: July 10, 2024

Showing 1-12 of 211

Last Updated: 09/26/2026